Anthony Fauci, MD, announced Monday he is stepping down in December 2022 from his various positions, including as head of the National Institute of Allergy and Infectious Diseases, “to pursue the next chapter of my career” and that he is not retiring.
Anthony Fauci, MD, announced Monday he is stepping down in December 2022 from the positions of director of the National Institute of Allergy and Infectious Diseases (NIAID), chief of the NIAID Laboratory of Immunoregulation, and chief medical advisor to the president.
Fauci, 81, said in a statement released by the National Institutes of Health that he is leaving “to pursue the next chapter of my career” and that he is not retiring.
“I want to use what I have learned as NIAID Director to continue to advance science and public health and to inspire and mentor the next generation of scientific leaders as they help prepare the world to face future infectious disease threats.”
Fauci began leading the NIAID 38 years ago under President Ronald Reagan. After Reagan, he served 6 more presidents, Republicans and Democrats alike, and oversaw reponses to HIV/AIDS, the West Nile virus, anthrax attacks, Ebola and Zika viruses, and the COVID-19 pandemic.
He was awarded the Presidential Medal of Freedom in 2008 by President George W. Bush.
In a statement, President Joe Biden praised Fauci’s long public service career, saying that as vice president, “I came to know him as a dedicated public servant, and a steady hand with wisdom and insight honed over decades at the forefront of some of our most dangerous and challenging public health crises.”
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More